In collaboration with OncoAlert, Dr Choueiri covers some of the interesting studies presented at the virtual ESMO 2020 on renal cancer.
He starts by discussing some of the important results from CheckMate 9ER and predicts that soon nivolumab and cabozantinib could become a standard of treatment for advanced renal cell carcinoma.
Dr Choueiri then moves to other studies that presented outcomes of different combination therapies on renal carcinoma.
He highlights the outcomes of a study based on circulating cell-free tumor DNA and how it can be used in diagnosis and evaluating prognosis.
Dr Choueiri wraps up by mentioning a French study on biomarkers and their role in targeted therapy and disease detection that can lead to future drug trials.
Follow OncoAlert on Twitter.
Read related news here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.